---
title: "Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294437888.md"
description: "Eli Lilly disclosed a 7.36% stake in Scribe Therapeutics via a Schedule 13D filing, combining convertible note conversions and IPO shares. The investment signals potential engagement with the newly public biotech firm. Eli Lilly holds the shares for investment purposes, may engage in hedging, and agreed to a 180-day lock-up. While planning discussions with Scribe's management, it currently has no specific plans for changes."
datetime: "2026-07-31T01:36:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294437888.md)
  - [en](https://longbridge.com/en/news/294437888.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294437888.md)
generator: "portal-rs"
---

# Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake

Eli Lilly and Company disclosed a 7.36% stake in Scribe Therapeutics, Inc. common stock. The position combines shares from a July 10, 2026 conversion of an 8% convertible note and 333,333 shares bought in Scribe’s July 23, 2026 IPO, according to a Schedule 13D filed on Jul. 30, 2026. The move links a major pharmaceutical company to Scribe following its IPO and signals potential engagement.

**Investor Intent**

Eli Lilly says it holds the shares for investment and may buy more or sell some in the future. The company may also use hedging tools, noting it "may engage in hedging or other transactions... including swaps and other derivative instruments."

Lilly agreed to a 180‑day lock-up from July 23, 2026, which limits sales or transfers without the underwriters’ consent. The company plans to "engage in discussions with directors, officers, members of management" and other stakeholders, may hire advisors, and currently has no specific plans for changes at Scribe.

**Investor's Background**

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company regularly partners with biotech firms and invests in innovative therapeutic platforms to expand its pipeline. Lilly focuses on areas such as diabetes, obesity, neuroscience, oncology, and immunology and has a long track record of large-scale drug development.

Original SEC Filing: Scribe Therapeutics, Inc. \[ SCTX \] - SCHEDULE 13D - Jul. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SCTX.US](https://longbridge.com/en/quote/SCTX.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)

## Related News & Research

- [Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs](https://longbridge.com/en/news/297082109.md)
- [BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million](https://longbridge.com/en/news/296992922.md)
- [Lilly's Cost-Saving Study Leaves Out Zepbound's Price](https://longbridge.com/en/news/297077502.md)
- [02:46 ETBioArctic: Interim Report for the period April - June 2026](https://longbridge.com/en/news/296997614.md)
- [Laekna Advances Obesity Drug LAE102 With Positive Phase I Data](https://longbridge.com/en/news/296933979.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**